Search results for "RAV"

showing 10 items of 5866 documents

Autoimmune thyroid disease: new models of cell death in autoimmunity

2002

Autoimmunity to thyroid antigens leads to two distinct pathogenic processes with opposing clinical outcomes: hypothyroidism in Hashimoto's thyroiditis and hyperthyroidism in Graves' disease. The high frequency of these diseases and easy accessibility of the thyroid gland has allowed the identification of key pathogenic mechanisms in organ-specific autoimmune diseases. In early investigations, antibody- and T-cell-mediated death mechanisms were proposed as being responsible for autoimmune thyrocyte depletion. Later, studies on apoptosis have provided new insights into autoimmune target destruction, indicating the involvement of death receptors and cytokine-regulated apoptotic pathways in the…

endocrine systemHistoryProgrammed cell deathFas Ligand Proteinendocrine system diseasesImmunologyThyroid GlandApoptosisAutoimmunityDiseasemedicine.disease_causeThyroiditisEducationAutoimmunityPathogenesisAntigenSettore MED/04 - PATOLOGIA GENERALEHumansMedicinefas ReceptorMembrane Glycoproteinsbiologybusiness.industryThyroidThyroiditis Autoimmunemedicine.diseaseGraves DiseaseComputer Science Applicationsmedicine.anatomical_structureModels AnimalImmunologybiology.proteinAntibodybusinessT-Lymphocytes CytotoxicNature Reviews Immunology
researchProduct

Plasticizer extraction of Taxol infusion solution from various infusion devices.

1996

Taxol solution extracts the plasticizer DEHP (di(2-ethylhexyl)phthalate) from polyvinyl chloride (PVC) materials. In order to minimize patient exposure to DEHP, Taxol solutions should be prepared and administered in PVC-free materials. Particulate matter may form in Taxol infusion solution over time, so that in-line filtration with microporous membranes not greater than 0.22 microns is advisable. The purpose of this study was to evaluate the suitability of various administration- and in-line filter-sets for Taxol application. The extent of leached DEHP was determined using a Reversed Phase HPLC assay specific for DEHP. The four tested administration-sets, labeled as PVC-free, were all found…

endocrine systemPaclitaxelDrug StoragePharmaceutical Sciencemacromolecular substancesPharmacyToxicologylaw.inventionchemistry.chemical_compoundlawPlasticizersMicroporous membranesDiethylhexyl PhthalateHumansPharmacology (medical)Infusions IntravenousFiltrationChromatography High Pressure LiquidDrug PackagingPharmacologyChromatographyInfusion solutionorganic chemicalsExtraction (chemistry)PhthalatePlasticizerGeneral MedicineReversed-phase chromatographyAntineoplastic Agents PhytogenicPolyvinyl chloridechemistryPharmacy worldscience : PWS
researchProduct

Response to methimazole in Graves' disease

1995

Summary OBJECTIVE A variety of regimens continue to be used In the treatment of Graves' disease with antithyrold drugs. We have lnvestigated the factors which determine the initial response to methimazole (time until euthyroidism Is achieved) In Graves' disease. PATIENTS Five hundred and nine patients with Graves' disease in different European countries with normal and subnormal iodine supply. Patients were randomized to treatment with either 10 or 40mg of methimazole per day for one year, with levothyroxine supplementation as required to maintain euthyroidism. Investigations were carried out before treatment and at 3 and 6 weeks and 3, 6, 9 and 12 months. MEASUREMENTS Response was assessed…

endocrine systemWolff–Chaikoff effectmedicine.medical_specialtyendocrine system diseasesbusiness.industryEndocrinology Diabetes and MetabolismAntithyroid agentmedicine.medical_treatmentGraves' diseaseThyroidLevothyroxinechemistry.chemical_elementIodinemedicine.diseaseAnti-thyroid autoantibodiesEndocrinologyEndocrinologymedicine.anatomical_structurechemistryInternal medicinemedicinebusinessmedicine.drugHormoneClinical Endocrinology
researchProduct

Thyroid Stimulating Hormone Receptor Antibodies in Thyroid Eye Disease-Methodology and Clinical Applications.

2018

Background Thyroid stimulating hormone receptor antibodies (TSHR-Ab) cause autoimmune hyperthyroidism and are prevalent in patients with related thyroid eye disease (TED). Purpose To provide a historical perspective on TSHR-Ab and to present evidence-based recommendations for clinical contemporary use. Methods The authors review the recent literature pertaining to TSHR-Ab in patients with TED and describe the various immunoassays currently used for detecting TSHR-Ab and their clinical applications. Results We provide a historical summary and description of the various methods used to detect TSHR-Ab, foremost, the functional TSHR-Ab. Increasing experimental and clinical data demonstrate the …

endocrine systemendocrine system diseasesEye disease030209 endocrinology & metabolismAutoimmunitymedicine.disease_causeBioinformaticsAutoimmunity03 medical and health sciences0302 clinical medicineMedicineAnimalsHumansClinical severityReceptorAutoantibodiesbiologybusiness.industryThyroidReceptors ThyrotropinGeneral Medicinemedicine.diseaseClinical diseaseeye diseasesThyroid stimulating hormone receptorGraves OphthalmopathyOphthalmologymedicine.anatomical_structure030220 oncology & carcinogenesisbiology.proteinSurgeryAntibodybusinesshormones hormone substitutes and hormone antagonistsOphthalmic plastic and reconstructive surgery
researchProduct

Acute selective ablation of rat insulin promoter-expressing (RIP HER ) neurons defines their orexigenic nature

2012

Rat insulin promoter (RIP)-expressing neurons in the hypothalamus control body weight and energy homeostasis. However, genetic approaches to study the role of these neurons have been limited by the fact that RIP expression is predominantly found in pancreatic β-cells, which impedes selective targeting of neurons. To define the function of hypothalamic RIP-expressing neurons, we set out to acutely and selectively eliminate them via diphtheria toxin-mediated ablation. Therefore, the diphtheria toxin receptor transgene was specifically expressed upon RIP-specific Cre recombination using a RIP-Cre line first described by Herrera (RIP HER -Cre) [Herrera PL (2000) Development 127:2317–2322]. Usi…

endocrine systemmedicine.medical_specialtyPituitary glandBiologyReal-Time Polymerase Chain ReactionEnergy homeostasisMiceArcuate nucleusOrexigenicInternal medicineWeight LossmedicineAnimalsInsulinPromoter Regions GeneticDorsomedial hypothalamic nucleusNeuronsDiphtheria toxinMultidisciplinarydigestive oral and skin physiologyArcuate Nucleus of HypothalamusFeeding BehaviorBiological SciencesGlucose Tolerance TestRatsEndocrinologymedicine.anatomical_structurenervous systemHypothalamusNucleushormones hormone substitutes and hormone antagonistsParaventricular Hypothalamic Nucleusmedicine.drugProceedings of the National Academy of Sciences
researchProduct

Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies.

2015

Cell-based bioassays for functional thyroid stimulating autoantibodies (TSAb) are sensitive diagnostic tools. However, there is no bioassay available that is standardized with international reference material. We aimed to promote the standardization of the test results among laboratories that perform TSAb bioassays and calibrate TSAb levels against the second international standard (IS) 08/204 from the National Institute for Biological Standards and Control (NIBSC).Serum TSAb activity was measured with a FDA-cleared bioassay that utilizes CHO cells expressing a chimeric thyrotropin receptor (TSHR) and a c-AMP response-element-dependent luciferase. The IS was applied for calibration. TSAb re…

endocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismCHO CellsDiagnostic toolsSensitivity and SpecificityThyrotropin receptorEndocrinologyCricetulusInternal medicineCricetinaeMedicineBioassayAnimalsHumansReceptorAutoantibodiesbiologybusiness.industryAutoantibodyReproducibility of ResultsReceptors Thyrotropineye diseasesGraves DiseaseEndocrinologybiology.proteinBiological AssayAntibodybusinessImmunoglobulins Thyroid-StimulatingThyroid : official journal of the American Thyroid Association
researchProduct

Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease

2021

Abstract Context We previously presented evidence that TSH receptor (TSHR)-stimulating autoantibodies (TSAbs) bind to and activate TSHRs but do not bind to IGF1 receptors (IGF1Rs). Nevertheless, we showed that IGF1Rs were involved in thyroid eye disease (TED) pathogenesis because TSAbs activated crosstalk between TSHR and IGF1R. Teprotumumab, originally generated to inhibit IGF1 binding to IGF1R, was recently approved for the treatment of TED (Tepezza). Objective To investigate the role of TSHR/IGF1R crosstalk in teprotumumab treatment of TED. Design We used orbital fibroblasts from patients with TED (TEDOFs) and measured stimulated hyaluronan (HA) secretion as a measure of orbital fibrobla…

endocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismClinical BiochemistryThyrotropinStimulationContext (language use)Antibodies Monoclonal HumanizedBiochemistryReceptor IGF Type 1EndocrinologyInternal medicinemedicineHumansHyaluronic AcidOnline Only ArticlesReceptorFibroblastInsulin-like growth factor 1 receptorGene knockdownTeprotumumabChemistryBiochemistry (medical)Receptors Thyrotropineye diseasesGraves Ophthalmopathybody regionsCrosstalk (biology)Endocrinologymedicine.anatomical_structuremedicine.drugThe Journal of Clinical Endocrinology & Metabolism
researchProduct

A Novel Long-Term Graves’ Disease Animal Model Confirmed by Functional Thyrotropin Receptor Antibodies

2020

<b><i>Introduction:</i></b> A novel long-term murine model for Graves’ disease (GD) using repeated, long-term immunizations with recombinant adenovirus expressing the extracellular A-subunit of the human thyrotropin receptor (Ad-TSHR) was applied to evaluate the functional anti-TSHR-antibody (TSHR-Ab) profile. <b><i>Methods:</i></b> BALB/c mice received 7 immunizations with either 10<sup>10</sup> plaque-forming units of Ad-TSHR or control Ad-GFP. Naïve (nonimmuized native) mice were also studied. Three 3-weekly immunizations were followed by 4-weekly boosts until the 7th immunization. Blocking (TBAb) and stimulating (TSAb) TSHR-Ab …

endocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismGraves' disease030209 endocrinology & metabolismlaw.inventionThyrotropin receptor03 medical and health sciences0302 clinical medicineAnimal modellawInternal medicinemedicineExtracellularmedicine.diagnostic_testbiologybusiness.industrymedicine.diseaseSerum sampleseye diseasesEndocrinology030220 oncology & carcinogenesisImmunoassaybiology.proteinRecombinant DNAAntibodybusinessResearch ArticleEuropean Thyroid Journal
researchProduct

Clinical Relevance of Thyroid-Stimulating Immunoglobulins in Graves' Ophthalmopathy

2011

Purpose Thyroid-stimulating immunoglobulins (TSIs) likely mediate Graves' ophthalmopathy (GO). The clinical relevance of these functional autoantibodies was assessed in GO. Design Cross-sectional trial. Participants A total of 108 untreated patients with GO. Methods Thyroid-stimulating immunoglobulins, assessed with a novel bioassay, bind to the thyrotropin receptor (TSHR) and transmit signals for cyclic adenosine monophosphate (cAMP)-dependent activation of luciferase gene expression. The cAMP/cAMP response element-binding protein/cAMP-regulatory element complex induces luciferase that is quantified after cell lysis. The TSI levels were correlated with activity and severity of GO and compa…

endocrine systemmedicine.medical_specialtyendocrine system diseasesbiologybusiness.industryGraves' diseaseAutoantibodymedicine.diseaseThyrotropin receptorGraves' ophthalmopathyOphthalmologychemistry.chemical_compoundEndocrinologychemistryInternal medicineImmunopathologyImmunologymedicinebiology.proteinThyroid Stimulating ImmunoglobulinCyclic adenosine monophosphateAntibodybusinessOphthalmology
researchProduct

Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study

1998

OBJECTIVE The optimal antithyroid drug regimen for Graves' disease remains a matter of controversy. The European Multicentre Trial Group has investigated the effects of methimazole drug dose on the long-term outcome of Graves' disease. DESIGN Extended follow-up of patients from a prospective multicentre trial, designed to study methimazole dose effects on the outcome of Graves' disease. We have reported previously that the relapse rates did not differ after a medication-free observation period of 12 months; the relapse rates were 37 and 38%, respectively. In this paper, we describe the outcome in these patients after a mean observation period of 4.3 ± 1.3 years and have looked for potential…

endocrine systemmedicine.medical_specialtyendocrine system diseasesbusiness.industryEndocrinology Diabetes and MetabolismAntithyroid agentmedicine.medical_treatmentGraves' diseaseUrinary systemThyroidLevothyroxinemedicine.diseaselaw.inventionClinical trialEndocrinologymedicine.anatomical_structureEndocrinologyRandomized controlled triallawInternal medicineMedicinebusinessProspective cohort studymedicine.drugClinical Endocrinology
researchProduct